Latest:
Dr. Jeffrey Trent on the Melanoma Dream Team
Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jeffrey M. Vainshtein, MD
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation
The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Jeffrey Zonder, MD
Jeffery Zonder, MD, is the leader of the Multiple Myeloma Sub-Committee at Barbara Ann Karmanos Cancer Institute and a professor of medicine in the Department of Hematology and Oncology at Wayne State University School of Medicine.
Latest:
Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma
Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.
Jeffrey Zweig, MD
Latest:
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?
With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.
Jena D. French, PhD
Latest:
Jena French on Combinations With Immunotherapy in Thyroid Cancer
Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.
Jennifer Bellon, MD
Latest:
Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment
Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.